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Serum hepatocyte growth factor as an index of disease
status of patients with colorectal carcinoma
T Fukuura, C Miki, T Inoue, K Matsumoto and H Suzuki
Department of Surgery II, Mie University Medical School, Tsu, Japan
Summary To evaluate the clinical significance of serum levels of hepatocyte growth factor (HGF) in colorectal cancer patients, we measured
the venous and portal concentrations of HGF in 60 patients. The tissue concentrations in the tumour and adjacent normal mucosa were also
determined. The serum HGF concentration for the peripheral venous blood of the patients was significantly higher than that in normal
controls. The content of HGF in cancer tissue was also significantly higher than that in normal mucosa, and it was correlated with the serum
HGF concentration for the peripheral venous blood. The serum concentration of HGF reflected pathological features, including tumour size
and lymph node or liver metastasis, and it showed an association with various preoperative nutritional parameters and the preoperative
haemoglobin level. The serum HGF concentration was also correlated with the serum concentrations of immunosuppressive acidic protein
and interleukin-6, indices of the host's immunological condition. Serum HGF seems to be a useful index of the disease status of patients with
colorectal carcinoma.
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Hepatocyte growth factor (HGF) is a multifunctional cytokine that
is the most potent known stimulator of hepatocyte growth and
DNA synthesis (Tsubouchi et al, 1991; Kaneko et al, 1992). HGF
has also been recognized as a tumour-disseminating factor
(Weidner et al, 1991; Mayer et al, 1993; Tannapfel et al, 1994). In
several experimental studies, evidence has been acquired ofa rela-
tion of HGF to the progression of tumour cells (Tajima et al,
1992). Among the particularly important biological activities of
HGF in tumour cells is its capacity to increase epithelial cell
proliferation and motility (Gherardi et al, 1990). In clinical studies,
a relationship between the concentration of HGF in serum or
cancer tissue and the progression of disease has been noted in
patients with gastric cancer (Taniguchi et al, 1997), oesophageal
cancer (Takada et al, 1995) and breast cancer (Yamashita et al,
1994; Taniguchi et al, 1995). However, there are no reports
regarding the clinical relevance ofHGF in patients with colorectal
carcinoma.
Malnutrition or immunosuppression are involved in the devel-
opment of life-threatening complications in patients with malig-
nancies (Braga et al, 1988; Nishi et al, 1988; Dannhauser et al,
1995; Triantafillidis et al, 1995; Windsor et al, 1995; Goransson et
al, 1996). Patients with advanced cancer and cachexia typically
demonstrate modestly increased rates of energy expenditure with
concomitant diminished food intake. These metabolic changes
may be due to mediators released by the tumour or by the host
(Keller, 1993). Recently, the role of cytokines in these metabolic
changes was emphasized (Gambardella et al, 1997). In addition,
the relationship between cytokines and an immunosuppressive
substance has also been highlighted (Tanaka et al, 1993).
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The objective of this study was to evaluate the relationship
between serum HGF concentration and clinicopathological para-
meters in patients with colorectal cancer. The study was also
designed to assess the relation ofthe HGF concentration to clinical
parameters reflecting the preoperative nutritional status and
immunological condition ofthe patients.
PATIENTS AND METHODS
A total of60 patients who underwent surgery for colorectal cancer
at Mie University Hospital were enrolled into the study. Thirty-one
of these patients were male. The mean age was 64.7 years (range
38-86 years). None of these patients had abnormal liver function
tests or had received nutritional support before surgery. The
location of the tumours and distant metastases was determined by
barium enema, colonoscopy, computerized tomography and
magnetic resonance imaging. The primary lesion was located in
the rectum in 27 of the patients, the sigmoid colon in 16, the
descending colon in three, the transverse colon in three, the
ascending colon in eight and the caecum in three. Eleven patients
were diagnosed as having a synchronous liver metastasis. Tumour
resection was carried out in all patients. Simultaneous partial
hepatectomy for liver metastasis was performed in three patients.
The histological diagnosis was based on morphological exami-
nation of haematoxylin and eosin-stained, routinely processed
specimens. The clinicopathological parameters studied for prog-
nostic value were age, tumour size, histological type, histological
grade, lymph node involvement, vessel involvement, distant
metastasis and the serum concentration of carcinoembryonic
antigen (CEA). Carcinomas were classified according to their
degree ofdifferentiation and Dukes' classification.
Peripheral venous blood samples were obtained before surgery
and 3 months after surgery. Portal blood samples were also
obtained intraoperatively, using a heparinized catheter introduced
into the portal vein through a peripheral branch of the mesenteric
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Table 1 The serum concentration of HGF and clinicopathological
parameters
No. of patients Mean value P
Lymph node metastasis
+ 29 0.441 + 0.052
31 0.309 + 0.026 0.0234
Lymph node involvement
+ 5 0.443 + 0.060
55 0.359 + 0.031 NS
Vessel involvement
+ 6 0.411 + 0.073
54 0.361 + 0.031 NS
Liver metastasis
+ 11 0.518 + 0.104
49 0.340 + 0.026 0.0188
Dukes' classification
A 14 0.319+ 0.041
B 18 0.292 + 0.032
C 14 0.384 + 0.047 0.0435
D 14 0.519+0.094 (Bvs D)
vein. Serum samples obtained from 20 normal healthy age- and
sex-matched volunteers were used as control samples. The blood
was allowed to clot, and the serum was separated by centrifugation
at 3000 r.p.m. and was stored at -80°C until assayed. Specimens of
22 primary colorectal carcinomas and adjacent normal colonic
mucosa, obtained from the same patients, were immediately
placed in liquid nitrogen and stored at -80°C until assayed.
The serum concentration of HGF was measured using an
enzyme-linked immunosorbent assay (ELISA) kit for human HGF
(Otsuka Assay Laboratories, Tokushima, Japan), with a sandwich
method consisting ofthree steps as reported previously (Yamashita
et al, 1994). The lower limit of detection is 0.1 ng ml-'. The tissue
concentration of HGF was determined as described previously
(Yamashita et al, 1993). Briefly, frozen tissue (0.2 g) was homoge-
nized and extracted with 50 mm Tris-HCl buffer (2 ml), pH 7.4,
containing 0.25% Triton X-100, and was separated by centrifuga-
tion at 10000 r.p.m. The supematant was used to measure the
concentrations of HGF and protein in tumour tissues and normal
mucosa, using the ELISA Kit and BCA Protein Assay Reagent Kit
(Pierce) respectively. The concentrations for the tumour tissues and
normal mucosa are expressed in units of ng per 100 mg ofprotein.
The serum concentration of interleukin (IL) 6 was determined
using an ELISA kit (Endogen, MA, USA). The serum concentra-
tion of immunosuppressive acid protein (IAP) was also deter-
mined by the method as described previously, using a commercial
kit (Kureha Chemical, Tokyo). Briefly, rabbit anti-IAP antiserum
containing 1.5% agar gel, pre-diluted to between 5% and 20%
with Veronal Buffer at pH 8.6, was prepared on a plastic plate, and
2.5 mm diameter wells were punched out. Five microlitres of the
samples was applied to each well after incubation for 48 h at 37°C
in a humid chamber. The value of the IAP was calculated using a
calibration curve against purified IAP (Matsumoto, 1988).
For the assessment of the general preoperative condition of the
patients, thebody mass index [BMI, weight(kg)/height' (m2)], the per
centbody weight loss (current total body weight loss divided by usual
body weight x100), and the preoperative levels of serum albumin,
cholinesterase (Ch-E) and haemoglobin (Hb) were determined.
Informed consent was obtained from each subject. The protocol
was approved by the Review Board ofour institute. The results are
presented as means ± s.e.m. and were submitted to one-way
analysis of variance followed by Scheffe's F-test. Correlations
were analysed by simple regression analysis. A P-value of < 0.05
was considered to be significant.
RESULTS
The mean concentration of serum HGF in the peripheral venous
blood of the patients was significantly higher than that in the
normal volunteers (0.373 + 0.030 vs 0.174 ± 0.014, P = 0.0003)
(Figure IA). The cut-off value was set at 0.296 ng mll (mean ± 2
s.d.). The serum concentration of HGF in the peripheral venous
blood was correlated with that in the portal venous blood (r =
0.612, P < 0.001). The serum HGF concentration in the peripheral
venous blood was elevated in 32 of the 60 patients (53.3%). In
contrast, the serum CEA level in the peripheral venous blood was
elevated in 27 patients (45%). The concentration of serum HGF
showed a slight association with the serum CEA level (r = 0.247,
P = 0.0573). In the patients who underwent curative tumour resec-
tion, the serum HGF concentration was significantly reduced post-
operatively (0.292 ± 0.024 preoperative level vs 0.236 +0.020,
P = 0.0156).
The concentration of HGF in cancer tissue ranged from 48.2 to
259.7 ng per 100 mg of protein and was significantly higher than
that in the normal mucosa (113.99 ± 11.13ng per 100mg of
protein vs 39.81 ± 4.51 ng per 100mg of protein, P <0.0001)
(Figure IB). The serum HGF concentration was correlated with
the HGF concentration in cancer tissue (r = 0.460, P = 0.0313),
whereas it was not correlated with the HGF concentration in the
normal mucosa (Figure 2).
Table 1 demonstrates the relationship between the serum HGF
concentration in the peripheral venous blood and the pathological
findings. The tumour diameter was correlated with the serum HGF
concentration (r = 0.310, P = 0.016). The serum concentration of
HGF in the patients with lymph node metastasis was significantly
higher than that in those without lymph node metastasis. It was
also significantly higher in the patients with liver metastasis than
in those without liver metastasis. Of 13 patients who died within a
Table 2 The relationship of the serum concentration of HGF to nutritional parameters
BMI Weight loss Alb (g dli-) ChE (mg dli-') Hb (g dl-)
(%)
Mean value 21.8 + 0.3 8.2 + 1.3 3.72 + 0.05 0.79 + 0.03 11.5 + 0.3
Correlation with HGF
P-value 0.389 0.385 0.259 -0.291 -0.257
r-value 0.0021 0.0024 0.0453 0.0242 0.0473
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Figure 1 (A) The serum HGF concentrations in healthy control subjects (n = 20) and in the patients with primary colorectal cancer (n = 60). (B) The tissue
HGF concentrations in the normal mucosa (n = 22) and in the tissue from the primary colorectal cancer tumour (n = 22). HGF, hepatocyte growth factor
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Figure 2 Relationship between tissue HGF concentrations and serum HGF
concentrations in the patients with primary colorectal cancer (n = 60). HGF,
hepatocyte growth factor
year after surgery, ten had exhibited preoperatively serum HGF
levels that were higher than the cut-off value (0.296 ng ml-').
The mean value of preoperative serum HGF levels in these 13
patients was significantly higher than that of the 38 patients who
survived more than 1 year after surgery (0.48 ± 0.09 ng ml-1 vs
0.32 ± 0.03 ng ml-', P = 0.0256 by ANOVA). In contrast to HGF, a
significant difference in concentration of CEA was found only
between the patients with and those without liver metastasis
(869.17 ± 651.05 vs 7.133 ± 10.19, P = 0.0055).
Table 2 shows the relationship between the serum HGF concen-
tration in the peripheral venous blood and each of the parameters
reflecting the preoperative nutritional condition of the patients.
The serum HGF concentration was correlated with the BMI, the
per cent body weight loss, the Hb level and the serum levels of
albumin and Ch-E.
The mean concentration of serum IL-6 in the peripheral blood
was 31.5 ± 9.5 pg ml-' (range 4.9-406.2 pg ml-'). There was a
significant correlation between the serum concentrations of HGF
and IL-6 (r = 0.374, P = 0.0049). The serum concentration ofIL-6
showed a weak negative association with the BMI (r = -0.259, P =
0.0561), but it showed no correlation with other nutritional para-
meters (Figure 3A).
The mean serum IAP concentration was 359.8 ± 24 gg ml-1
(range 62.5-1112.5 ,ug ml-'). A significant relationship was found
between the serum concentrations ofIAP and HGF (r = 0.548, P <
0.0001) (Figure 3B).
DISCUSSION
Gohda et al (1986) have purified HGF from human plasma and
determined that it exists in multiple forms, with molecular mass
ranging from 76 to 92 kDa. These consist of two chains linked
together by disulphide bonds. Recent studies have suggested that
HGF is produced by non-parenchymal hepatic cells including
Kupffer cells (Noji et al, 1990), endothelial cells (Stoker et al,
1987; Shima et al, 1991), fibroblasts and fat-storing cells in the
liver (Ramadori et al, 1992; Schirmacher et al, 1992), endothelial
cells in the lung (Matsumoto et al, 1992; Yanagita et al, 1992).
Experimentally, tumour cells are also known to produce HGF;
HGF or mRNA encoding this factor has been detected in fibro-
sarcoma (Stoker et al, 1987), lung cancer (Yoshinaga et al, 1992;
Rygaard et al, 1993; Tsao et al, 1993); hepatoma (Miyazaki et al,
1991) and pancreatic cancer cells (Hirota et al, 1993). Other
normal tissues, such as the pancreas, small intestine, thyroid, brain
and submaxillary salivary gland are also known to produce HGF
(Zarmegar et al, 1990; Wolfet al, 1991).
Experimentally, proinflammatory cytokines, such as IL-13 and
IL-6, up-regulate HGF production in stromal cells (Tamura et al,
1993; Maas-Szabowski et al, 1996; Ohira et al, 1996; Sugiyama et
al, 1996; Weng et al, 1997). A recent study has demonstrated that
IL-I plays a certain role in inducing HGF expression in stromal
fibroblasts, which may eventually lead to invasive growth in carci-
noma cells through tumour-stroma interactions (Nakamura et al,
1997). In the present study, there was a significant correlation
between the serum concentration ofHGF and IL-6, suggesting that
the cancer-stroma interaction through IL-6 and HGF may exist in
colorectal carcinoma.
The expression of HGF receptor is also enhanced in digestive
cancers, lung cancer and breast cancer (Beviglia et al, 1997;
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Figure 3 (A) Relationship between serum IL-6 levels and serum HGF concentrations in the patients with primary colorectal cancer (n = 60). (B) Relationship
between serum IAP levels and serum HGF concentrations in the patients with primary colorectal cancer (n = 60). HGF, hepatocyte growth factor; IL-6,
interleukin 6; IAP, immunosuppressive acidic protein
Galeazzi et al, 1997; Jin et al, 1997; Kienne et al, 1997; Naka et al,
1997; Pisters et al, 1997; Ueki et al, 1997). HGF receptor was
consistently and significantly overexpressed in colon carcinomas
and adenomas, suggesting that overexpression of this proto-
oncogene may have mechanistic significance in the early stage of
human colorectal carcinogenesis (Liu et al, 1992).
There is some evidence for a pivotal role of HGF in the regula-
tion of the cell motility, and as a mitogen and motogen for certain
epithelial cells and vascular endothelial cells in culture (Stoker et
al, 1987; Rosen et al, 1990a). HGF prevented loss of cell viability
and morphological damage and retarded DNA fragmentation in
confluent C2.8 cells (Rovoltella et al, 1993).
As cell motility is a basic requirement for the establishment of
distant metastases by cancer cells (Schiffmann et al, 1990), the
capacity of HGF to induce motility in various cancer cells has
understandably raised interest (Jiang et al, 1993). Some cancer cell
lines show sensitivity to HGF (Rosen et al, 1990b; Weidner et al,
1990), and in fact HGF increased the invasiveness of cancer cells
in vitro in an invasion assay system (Weidner et al, 1990). Another
important aspect of cancer growth and metastasis is the establish-
ment of neovasculature by angiogenesis (Blood et al, 1990). By
inducing endothelial cell proliferation and motility, HGF can stim-
ulate neovascularization in vivo (Bussolino et al, 1992; Grant et al,
1993). These findings suggest that HGF, apart from increasing
the invasiveness of cancer cells, may also stimulate primary and
secondary tumour growth by modulating the tumour matrix (Jiang
et al, 1993).
A large amount of HGF has been detected in tissue extracts
from human breast cancer (Yamashita et al, 1993). In patients with
breast cancer, the HGF concentration in cancer tissue was corre-
lated with the tumour size, and, furthermore, the tissue concentra-
tion of HGF was the most important independent factor in the
prediction of relapse-free and overall survival (Yamashita et al,
1994). Among patients with oesophageal cancer, the 2-year crude
survival rate was lower in those with high concentrations of HGF
in cancer tissue compared with those with low concentrations
(Takada et al, 1995).
In the present study, the serum HGF concentration in the periph-
eral venous blood was correlated with the concentration of HGF in
the portal blood and in the cancer tissue. Moreover, the serum
HGF concentration was correlated with the tumour diameter. Our
findings suggest that the serum HGF concentration in the periph-
eral venous blood may reflect the content of HGF in the tumour
component, and that the increase in the circulating level may be
associated with tumour proliferation. The present study also
revealed that the serum HGF concentration was significantly
higher in the patients with lymph node or liver metastasis. In
contrast with the HGF concentration, the serum CEA level
reflected only whether liver metastasis was present. These obser-
vations seem to support the hypothesis that serum HGF is a potent
tumour marker in evaluating the tumour progression of colorectal
carcinoma.
Interestingly, the serum HGF concentration was also correlated
with various nutritional parameters, such as the BMI, the per cent
body weight loss, and serum levels of albumin and Ch-E. There is
some evidence that proinflammatory cytokines, especially IL-6,
act as endogenous pyogens (Gauldie et al, 1987; Castel et al, 1990)
and mediate experimental cachexia from cancer (Strassmann et al,
1992). IL-6 affects systemic nutrition and metabolism and is
responsible for many of the clinically observed nutritional effects
of injury, infection and cancer (Souba, 1994; Yanagawa et al,
1995; Oka et al, 1996). As a significant correlation was found
between the serum concentration of HGF and IL-6 in the present
study, our findings suggest that serum HGF may be a possible
index that reflects tumour-induced malnutrition developed in the
patients with advanced colorectal carcinoma.
IAP, a glycoprotein with a molecular weight of 50 000,
suppresses various immune responses in vitro and in vivo (Tamura
et al, 1981). A negative correlation was found between peripheral
blood natural killer cell activity and serum IAP level in patients
with oesophageal carcinoma (Oka et al, 1993). The serum IAP
level, used as an index of the host's immunity, demonstrated clear
increases with the progression of cancer (Shibata et al, 1993). In
our study, serum HGF concentration in the peripheral blood was
correlated significantly with the serum IAP level, suggesting that
serum HGF in colorectal cancer patients also reflects tumour-
induced immunological deterioration.
In conclusion, in patients with colorectal cancer the serum HGF
concentration seems to reflect pathological features of the tumour
as well as the general preoperative condition of the patient,
British Journal of Cancer (1998) 78(4), 454-459
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including nutritional and immunological status. Serum HGF may
be a specific and sensitive index in evaluating the disease status of
patients with colorectal carcinoma.
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